ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Interim Analysis of the PREVENT Study: Real World Prospective Data from Children and Adolescents with Haemophilia A or B Treated with Recombinant Factor VIII Fc (rFVIIIFc) or Recombinant Factor IX Fc (rFIXFc)

C. Heller1, C. Bidlingmaier2, C. Escuriola3, N. Hagedorn4, J. Oldenburg5, J. van den Boom6, H. Malmström7, E. Santagostino8, A. Tiede9

1Department of Pediatric Hematology/Oncology/Haemostaseology, University Hospital of Frankfurt, Frankfurt, Germany, 2Dr. von Hauner’s Children’s Hospital, Paediatric Haemophilia Centre, Munich, Germany, 3Haemophilia Centre Rhein Main (HZRM), Mörfelden-Walldorf, Germany, 4Charité - Universitätsmedizin Berlin, Department of Pediatrics, Division of Oncology and Hematology, Berlin, Germany, 5Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn AöR, Bonn, Germany, 6Swedish Orphan Biovitrum GmbH, Martinsried, Germany, 7Swedish Orphan Biovitrum AB, Stockholm, Sweden, 8Swedish Orphan Biovitrum AG, Basel, Switzerland, 9Department of Hematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Abstract Number: PB0506

Meeting: ISTH 2021 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Safety and efficacy of rFVIIIFc and rFIXFc were established in phase 3 trials. The PREVENT study prospectively evaluates real-world usage and effectiveness of rFVIIIFc and rFIXFc in Germany over 24-months in patients with haemophilia A (PwHA) or B (PwHB).

Aims: Providing first interim analysis of the paediatric population (<18 years) with at least 9 months of prospective observation.

Methods: PREVENT (NCT03055611) was approved by medical ethics committees. Informed consent was obtained from all patients/caregivers. Primary endpoints are annualised bleeding rate (ABR), injection frequency and factor consumption. Secondary endpoints include reason for initiating rFVIIIFc or rFIXFc treatment. The interim analysis (data cut September 24, 2020) used descriptive statistics.

Results: ​​​​The analysis included 55 PwHA and 10 PwHB, with median (range) age of 8.0 (0-17) and 11.5 (3-15) years, respectively. Forty-nine (89%) PwHA and 6 (60%) PwHB were severe. Inhibitor history prior to rFVIIIFc/rFIXFc initiation was reported in 12 (21.8%) severe PwHA and none among PwHB. No inhibitors had been detected at time of data cut.
Median ABR and joint ABR were low for PwHA and PwHB (table 1), during a median (range) follow-up of 18.9 (9.3-23.3) and 20.1 (10.5-23.7) months, respectively. For this follow-up period, the proportion of zero joint bleeds were 63.6 % in PwHA and 40.0 % in PwHB.  
Median injection frequency and factor consumption are shown in table 1.
Most patients and physicians were satisfied or highly satisfied with the treatment (table 1).
Main reason for initiating rFVIIIFc or rFIXFc treatment was to reduce injection frequency while maintaining protection from bleeds (table 2).
 

Haemophilia A (N=55)a Haemophilia B (N=10)a
n n
ABR, median (Q1;Q3) 55 0.6 (0.0;1.8) 10 1.9 (0.6;4.6)
Joint ABR, median (Q1;Q3) 55 0.0 (0.0;0.6) 10 0.6 (0.0;1.0)
Weekly injection frequency, median (Q1;Q3) 55 2.3 (2.0;3.0) 10 1.0 (1.0;1.0)
Weekly consumption (IU/kg/week), median (Q1;Q3) 53 102.0 (86.9;126.6) 10 55.0 (44.3;73.9)
Physicians satisfied or highly satisfied with treatment after 1 year, n (%) 42 39 (93) 8 8 (100)
Patients satisfied or highly satisfied with treatment after 1 year, n (%)b 13 11 (85) 6 6 (100)
aFor some of the outcomes data were not available for all patients at the interim data cut.
bCompletion of all patient-reported outcomes was optional.

Clinical outcomes and treatment of paediatric patients on prophylaxis with rFVIIIFc or rFIXFc

Haemophilia A (N=55) Haemophilia B (N=10)
Improve protection from bleeds 12 (21.8%) 1 (10.0%)
Improve protection to increase physical activity level 1 (1.8%) 0 (0.0%)
Reduce injection frequency while maintaining protection from bleeds 42 (76.4%) 9 (90.0%)

Reason for treatment initiation with rFVIIIFc or rFIXFc

Conclusions: Treatment with rFVIIIFc or rFIXFc in children and adolescents provided a high level of protection from bleeds with low injection frequency. This interim analysis of the real-world use of rFVIIIFc and rFIXFc for up to 2 years reinforces the results of the pivotal trials.

To cite this abstract in AMA style:

Heller C, Bidlingmaier C, Escuriola C, Hagedorn N, Oldenburg J, van den Boom J, Malmström H, Santagostino E, Tiede A. Interim Analysis of the PREVENT Study: Real World Prospective Data from Children and Adolescents with Haemophilia A or B Treated with Recombinant Factor VIII Fc (rFVIIIFc) or Recombinant Factor IX Fc (rFIXFc) [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/interim-analysis-of-the-prevent-study-real-world-prospective-data-from-children-and-adolescents-with-haemophilia-a-or-b-treated-with-recombinant-factor-viii-fc-rfviiifc-or-recombinant-factor-ix-fc/. Accessed August 15, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/interim-analysis-of-the-prevent-study-real-world-prospective-data-from-children-and-adolescents-with-haemophilia-a-or-b-treated-with-recombinant-factor-viii-fc-rfviiifc-or-recombinant-factor-ix-fc/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley